Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 107M P/E - EPS this Y 52.90% Ern Qtrly Grth -
Income -37.45M Forward P/E 9.60 EPS next Y - 50D Avg Chg 20.00%
Sales 1.43M PEG - EPS past 5Y - 200D Avg Chg 18.00%
Dividend N/A Price/Book 0.99 EPS next 5Y - 52W High Chg -15.00%
Recommedations 1.70 Quick Ratio 0.67 Shares Outstanding 586.92M 52W Low Chg 102.00%
Insider Own 23.42% ROA -32.81% Shares Float 354.17M Beta 1.57
Inst Own 13.91% ROE -57.70% Shares Shorted/Prior 10.43M/1.88M Price 0.38
Gross Margin 100.00% Profit Margin - Avg. Volume 278,531 Target Price 1.57
Oper. Margin -2,855.02% Earnings Date - Volume 145,041 Change 0.00%
About IsoRay, Inc.

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

IsoRay, Inc. News
04/30/24 Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs
04/08/24 Perspective Therapeutics to Participate at Upcoming April Investor Conferences
03/30/24 Perspective Therapeutics Inc (CATX) Reports Fiscal Year 2023 Financial Results
03/28/24 Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
03/19/24 Heard on the Street: Pharma Goes Radioactive as AstraZeneca Announces Fusion Deal
03/18/24 Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma
03/11/24 Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024
03/05/24 Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility
03/04/24 Perspective Therapeutics Announces $87.4 Million Private Placement
02/26/24 Perspective Therapeutics to Participate at Upcoming Investor Conferences
02/20/24 These Drug Companies Are Going Nuclear to Fight Cancer
02/13/24 PTC Therapeutics (PTCT) to Report Q4 Results: Wall Street Expects Earnings Growth
02/12/24 Perspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
02/08/24 Earnings Preview: Perspective Therapeutics (CATX) Q4 Earnings Expected to Decline
02/01/24 Perspective Therapeutics Introduces “Pre-Targeting” Theranostic Technology Platform
01/30/24 Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year?
01/22/24 Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement
01/18/24 Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement
01/17/24 Perspective Therapeutics Announces Proposed Public Offering
01/17/24 Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT-α-NET and [(212)Pb]VMT01
CATX Chatroom

User Image sck2 Posted - 5 hours ago

$CATX 🕵️‍♂️

User Image TheStickerGuy Posted - 6 hours ago

$CATX The only thing swirled higher than this stock is the ice cream I'm eating right now at the Car Show.

User Image sck2 Posted - 7 hours ago

$CATX ✅💪🕵️‍♂️

User Image sck2 Posted - 7 hours ago

$CATX coiled and ready 💥✅💪🐂

User Image GI197845 Posted - 7 hours ago

$CATX

User Image Sayknee Posted - 8 hours ago

$CATX Let that sink in…Another brilliant move was cutting a deal with Lantheus. That put us on the map, bigtime with heavy hitters taking a notice of what we have coming.. *The clinical collaboration with Bristol Meyers. *The agreement with Stoney Brook University The agreement with the Mayo Clinic Along with the financial meetings and manuvering to get the company financed for the next 2 years.. Brilliant!

User Image Sayknee Posted - 8 hours ago

$CATX The pivot away from C-131 isotope and buying Radio pharmaceutical was brilliant! IMHO. GT Medical now has that technology, and we have the ability to introduce to the world, a really great technology, in it’s own right, to help in one more step in the treatment of Cancer. Just like I think Gammatile should be the new standard of care for operable brain tumors, (limited to USA and maybe Canada, slow adaption as its too expensive and only 100 or so out of 350. Hospital CFO’s and radiation oncologist hate it..It’s very disruptive to the prior mentioned above, $$$$ our new technology has that very same potential. Once approved, we’ll be embraced by the Rad Once, as they wont get cut out of the $$$ in a WORLD WIDE market..

User Image GoEagles1 Posted - 9 hours ago

$CATX New high after hours? Yes, please.

User Image Sayknee Posted - 9 hours ago

$CATX Forgot…got to admit I bought some RDGL last week. Got a double! Thanks for tge heads up…Interesting company..If they get approved for human trials…LOOK OUT!

User Image Sayknee Posted - 9 hours ago

$CATX I know its not the normal, but, still traded 3.82 million shares today..As an old timer here, We remember The days when less than 100K shares traded for .30 to .40…Not gonna hear me complain about the last 4 months…with all the good news coming out and continuing to come out…I think we in the Goose that lays all the Golden eggs. IMHO

User Image GoEagles1 Posted - 9 hours ago

$CATX I'm anxious to see what we open at tomorrow.

User Image TonyFish Posted - 10 hours ago

$CATX Now that we are Billion ares what are we going to buy when this settles? Maybe in a year.

User Image sck2 Posted - 10 hours ago

$CATX what did he say ... for we can't break 1.75?!?!?!

User Image rughead64 Posted - 10 hours ago

$CATX 175

User Image GoEagles1 Posted - 10 hours ago

$CATX It's good to be on Team CATX, even on the dips. And a board of mostly lovely people here!

User Image MoonShine007 Posted - 10 hours ago

$CATX $RGLS need volume. Any news will send them both to MARS.

User Image GoEagles1 Posted - 10 hours ago

$CATX I can't believe this is happening. Never thought we'd hit 1.74....and on nearly half the volume!

User Image sck2 Posted - 10 hours ago

$CATX LG !!!

User Image TonyFish Posted - 10 hours ago

$CATX Dont think we are done yet for the day. Strong chart. Could be wrong so.

User Image sck2 Posted - 10 hours ago

$CATX ✅💪🕵️‍♂️🐂

User Image JDinvestments Posted - 11 hours ago

$CATX yesterday’s news worthy of $2.50 plus STRONG BUYOUT 🔥🔥🔥💰💰💰🚀🚀🚀🥂🥂🥂

User Image Alacrity2 Posted - 11 hours ago

$CATX I have seen drugs get fast track before and the stock goes wild … but not catx…. I read a comment on linked in comparing perspective Product to pembrolizumab (Keytruda) … that is pretty impressive results … I wonder what big news is lingering?

User Image luke_trader Posted - 11 hours ago

$CTMX 👉 $CATX Next 👇chart 📈

User Image GoEagles1 Posted - 12 hours ago

$CATX Volume is half what we usually are at this time of the day. It wants to run but can't get traction.

User Image TonyFish Posted - 12 hours ago

@Sidetracker Look @ $CATX. ^ month chart @ nothing but great news since December. Best buy of the year.

User Image Alacrity2 Posted - 13 hours ago

$CATX $RDGL awesome week and nothing but good news!

User Image Freddie___Mac Posted - 13 hours ago

$DRTS Rare buying opportunity in radiopharma. Treatment of solid tumors, already proven effective for certain indications. Valuation discrepancy to $CATX does not makes sense! $DRTS is well ahead with their clinical programs. Looking for more data readouts!

User Image jive_turkey Posted - 13 hours ago

$CATX Getting the cat ready.

User Image TheStickerGuy Posted - 14 hours ago

$CATX Somebody get keepyershirton out of Zed's basement. Check the trunk.

User Image GoEagles1 Posted - 15 hours ago

@Hereinbama35 Me, too. I buy, they tank. But I am in on $CATX and it's been making nice gains for months. Come on over on a dip.

Analyst Ratings
B. Riley Securities Buy Apr 9, 24
Oppenheimer Outperform Apr 1, 24
Oppenheimer Outperform Mar 19, 24
B. Riley Securities Buy Jan 26, 24
JonesTrading Buy Nov 15, 23
Oppenheimer Outperform May 19, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Williamson Robert F III Director Director Jan 30 Buy 0.71 127,206 90,316 338,761 02/01/24
Williamson Robert F III Director Director Jan 26 Buy 0.6 135,879 81,527 211,555 01/30/24
Puhlmann Markus Chief Medical Office.. Chief Medical Officer Jan 24 Buy 0.49960 280,000 139,888 1,375,425 01/26/24
Williamson Robert F III Director Director Jan 24 Buy 0.49 51,996 25,478 75,676 01/26/24
Williamson Robert F III Director Director Dec 21 Buy 0.3283 3,663 1,203 3,663 12/26/23
Hunt Jonathan Robert Chief Financial Offi.. Chief Financial Officer Dec 18 Buy 0.2587 125,000 32,338 316,710 12/19/23
Williamson Robert F III Director Director Dec 18 Buy 0.29 23,680 6,867 23,680 12/19/23
Puhlmann Markus Chief Medical Office.. Chief Medical Officer Dec 15 Buy 0.29 595,425 172,673 1,095,425 12/19/23
Woods Lori A Director Director Apr 13 Option 0.61 187,500 114,375 1,334,538 04/19/23
Hunt Jonathan Robert Chief Financial Offi.. Chief Financial Officer Dec 01 Buy 0.38 85,404 32,454 191,710 12/05/22
Streeter Jennifer COO & VP of HR COO & VP of HR Aug 18 Option 0.43 50,000 21,500 87,940 08/19/22
Streeter Jennifer COO & VP of HR COO & VP of HR Aug 05 Option 0.33 22,500 7,425 27,940 08/10/22
Austin Mark John VP Finance/Prin Fin&.. VP Finance/Prin Fin&Acct Offic Jun 08 Buy 0.29 18,800 5,452 54,030 06/09/22
Woods Lori A CEO CEO Jun 07 Buy 0.29640 75,000 22,230 1,047,038 06/09/22
Hunt Jonathan Robert Chief Financial Offi.. Chief Financial Officer Jun 07 Buy 0.28 39,000 10,920 106,306 06/09/22
Woods Lori A CEO CEO Nov 23 Option 0.45 125,000 56,250 972,038 11/24/21